Influence of fluvastatin on bone formation induced by demineralized bone matrix in mice

Pharmacological Reports

Volumn 58, Issue 3, 2006, Pages 443-447

  Galus, Ryszard ^a,b   Włodarski, Paweł ^a   Włodarski, Krzysztof H ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Demineralized bone matrix; Fluvastatin; Heterotopic bone formation; Mice; Statins

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEMINERALIZATION; BONE MASS; BONE MATRIX; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HETEROTOPIC OSSIFICATION; HYDROLYSIS; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; OSSIFICATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33746377326     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ayers DC, Evarts CM, Parkinson JR: The prevention of heterotopic ossification in high-risk patients by low-dose radiation therapy after total hip arthroplasty. J Bone Joint Surg Am, 1986, 68, 1423-1430.
2. Bidner SM, Rubins IM, Desjardins JV, Zukor DJ, Goltzman D: Evidence for a humoral mechanism for enhanced osteogenesis after head injury. J Bone Joint Surg Am, 1990, 72, 1144-1149.
3. Blum B, Moseley J, Miller L, Richelsoph K, Haggard W: Measurement of bone morphogenetic proteins and other growth factors in demineralized bone matrix. Orthopedics, 2004, 27, Suppl 1, S161-SI65.
4. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ et al.: Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 2000, 24, 2185-2188.
5. Cooley BC, Daley RA, Toth JM: Long-term BMP-2-induced bone formation in rat island and free flaps. Microsurgery 2005, 25, 167-173.
6. Davignon J, Mabile L: Mechanism of action of statins and their pleiotropic effects. Ann Endocrinol (Paris), 2001, 62, 101-112.
7. Edwards CJ: Statins and bone morphogenetic proteins: new pathways in bone formation. Ann Acad Med Singapore, 2002, 31, 245-247.
8. Garland DE: Clinical observations on fractures and heterotopic ossification in the spinal cord and traumatic brain injured populations. Clin Orthop Relat Res, 1988, 233, 86-101.
9. Harwin SF, Stein AJ, Stern RE, Kulick RG: Heterotopic ossification following primary total knee arthroplasty. J Arthroplasty, 1993, 8, 113-116.
10. Hasegawa M, Ohashi T, Uchida A: Heterotopic ossification around distal femur after total knee arthroplasty. Arch Orthop Trauma Surg, 2002, 122, 274-278.
11. Kawai M, Bessho K, Kaihara S, Sonobe J, Oda K, Iizuka T, Maruyama H: Ectopic bone formation by human bone morphogenetic protein-2 gene transfer to skeletal muscle using transcutaneous electroporation. Hum Gene Ther, 2003, 14, 1547-1556.
12. Kjaersgaard-Andersen P, Frich LH, Sojbjerg JO, Sneppen O: Heterotopic bone formation following total shoulder arthroplasty. J Arthroplasty, 1989, 4, 99-104.
13. Klein BY, Shohami E, Reikhinshtein Y, Ben-Bassat H, Liebergall M: Serum-mediated osteogenic effects of head injury on cultured rat marrow stromal cells. Calcif Tissue Int, 1999, 65, 217-222.
14. Kolbl O, Knelles D, Barthel T, Raunecker F, Flentje M, Eulert J: Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial. Int J Radiat Oncol Biol Phys, 1998, 42, 397-401.
15. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B et al.: Stimulation of bone formation in vitro and in rodents by statins. Science, 1999, 286, 1946-1949.
16. Nakamura Y, Tensho K, Nakaya H, Nawata M, Okabe T, Wakitani S: Low dose fibroblast growth factor-2 (FGF-2) enhances bone morphogenetic protein-2 (BMP-2)-induced ectopic bone formation in mice. Bone, 2005, 36, 399-407.
17. Ohno T, Shigetomi M, Ihara K, Matsunaga T, Hashimoto T, Kawano H, Sugiyama T et al.: Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats. Transplantation, 2003, 76, 869-871.
18. Osuga J: Statin and bone metabolism. Clin Calcium, 2004, 14, 235-240.
19. Otfinowski J: Heterotopic induction of osteogenesis in the course of neural injury. Patol Pol, 1993, 44, 133-168.
20. Phillips BW, Belmonte N, Vemochet C, Ailhaud G, Dani C: Compactin enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res Commun, 2001, 284, 478-484.
21. Rader CP, Barthel T, Haase M, Scheidler M, Eulert J: Heterotopic ossification after total knee arthroplasty. 54/615 cases after 1-6 years' follow-up. Acta Orthop Scand,1997, 68, 46-50.
22. Reddi AH, Wientroub S, Muthukumaran N: Biologic principles of bone induction. Orthop Clin North Am, 1987, 18, 207-212.
23. Romano CL, Duci D, Romano D, Mazza M, Meani E: Celecoxib versus indomethacin in the prevention of heterotopic ossification after total hip arthroplasty. J Arthroplasty, 2004, 19, 14-18.
24. Sampath TK, Reddi AH: Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. Proc Natl Acad Sci USA, 1983, 80, 6591-6595.
25. Sawyer JR, Myers MA, Rosier RN, Puzas JE: Heterotopic ossification: clinical and cellular aspects. Calcif Tissue Int, 1991, 49, 208-215.
26. Skoglund B, Forslund C, Aspenberg P: Simvastatin improves fracture healing in mice. J Bone Miner Res, 2002, 17, 2004-2008.
27. Sperling JW, Cofield RH, Rowland CM: Heterotopic ossification after total shoulder arthroplasty. J Arthroplasty, 2000, 15, 179-182.
28. Staal A, Frith JC, French MH, Swartz J, Gungor T, Harrity TW, Tamasi J et al.: The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res, 2003, 18, 88-96.
29. Takahashi K: Bone morphogenetic protein (BMP): from basic studies to clinical approaches. Nippon Yakurigaku Zasshi, 2000, 116, 232-240.
30. Trentz OA, Handschin AE, Bestmann L, Hoerstrup SP, Trentz OL, Platz A: Influence of brain injury on early posttraumatic bone metabolism. Crit Care Med, 2005, 33, 399-406.
31. Wang EA: Bone morphogenetic proteins (BMPs): therapeutic potential in healing bony defects. Trends Biotechnol, 1993, 11, 379-383.
32. Wang EA, Rosen V, Cordes P, Hewick RM, Kriz MJ, Luxenberg DP, Sibley BS, Wozney JM: Purification and characterization of other distinct bone-inducing factors. Proc Natl Acad Sci USA, 1988, 85, 9484-9488.
33. Wang GJ, Chung KC, Shen WJ: Lipid clearing agents in steroid-induced osteoporosis. J Formos Med Assoc, 1995, 94, 589-592.
34. Wang X, Tokuda H, Hatakeyama D, Hirade K, Niwa M, Ito H, Kato K et al.: Mechanism of simvastatin on induction of heat shock protein in osteoblasts. Arch Biochem Biophys, 2003, 415, 6-13.
35. Wildburger R, Zarkovic N, Tonkovic G, Skoric T, Frech S, Hartleb M, Loncaric I et al.: Post-traumatic hormonal disturbances: prolactin as a link between head injury and enhanced osteogenesis. J Endocrinol Invest, 1998, 21, 78-86.
36. Wong RW, Rabie AB: Early healing pattern of statininduced osteogenesis. Br J Oral Maxillofac Surg, 2005, 43, 46-50.
37. Youssefian T, Sapena R, Carlier R, Bos C, Denormandie A, Denys P, Cormier A et al.: Nodular osteochondrogenic activity in soft tissue surrounding osteoma in neurogenic para osteo-arthropathy: morphological and immunohistochemical study. BMC Musculoskelet Disord, 2004, 25, 5, 46.